About Peroxisomal 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing]
Peroxisomal 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing] (DECR2) is a protein
from Homo sapiens identified by UniProt accession
Q9NUI1, 292 residues long.
MolForge cross-references it against 0 known binders and
41 disease associations.
Target properties
| Protein name | Peroxisomal 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing] |
|---|
| UniProt accession | Q9NUI1 |
|---|
| Gene | DECR2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 292 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (41)
Diseases linked to this target (Open Targets).
- mean corpuscular hemoglobin · score 0.38
- mean corpuscular volume · score 0.37
- protein measurement · score 0.27
- urate measurement · score 0.16
- urinary metabolite measurement · score 0.16
- erythrocyte count · score 0.10
- platelet count · score 0.06
- mean platelet volume · score 0.06
- sphingomyelin measurement · score 0.05
- platelet component distribution width · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-Q9NUI1-F1 | alphafold | PREDICTED | 95.71 | — |
Amino-acid sequence (292 residues)
MAQPPPDVEG DDCLPAYRHL FCPDLLRDKV AFITGGGSGI GFRIAEIFMR HGCHTVIASR SLPRVLTAAR KLAGATGRRC LPLSMDVRAP PAVMAAVDQA LKEFGRIDIL INCAAGNFLC PAGALSFNAF KTVMDIDTSG TFNVSRVLYE KFFRDHGGVI VNITATLGNR GQALQVHAGS AKAAVDAMTR HLAVEWGPQN IRVNSLAPGP ISGTEGLRRL GGPQASLSTK VTASPLQRLG NKTEIAHSVL YLASPLASYV TGAVLVADGG AWLTFPNGVK GLPDFASFSA KL
Explore Peroxisomal 2,4-dienoyl-CoA reductase [(3E)-enoyl-CoA-producing] with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets